Caffeine citrate - Nippon Boehringer/Nobelpharma

Drug Profile

Caffeine citrate - Nippon Boehringer/Nobelpharma

Alternative Names: Anhydrous caffeine - Nobelpharma/Nippon Boehringer; NPC-11; Respia

Latest Information Update: 01 Jun 2016

Price : $50

At a glance

  • Originator Nippon Boehringer Ingelheim
  • Developer Nippon Boehringer Ingelheim; Nobelpharma
  • Class Respiratory stimulants; Small molecules; Xanthines
  • Mechanism of Action Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Apnoea
  • New Molecular Entity No

Highest Development Phases

  • Marketed Apnoea

Most Recent Events

  • 24 Mar 2014 Registered for Apnoea (In neonates) in Japan (PO)
  • 24 Mar 2014 Registered for Apnoea (In neonates) in Japan (IV)
  • 31 Oct 2012 Nobelpharma completes a phase III trial in Apnoea (In neonates) in Japan (NCT01408173)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top